Navigation Links
Can EP4 agonist alleviate gastric lesions?
Date:11/18/2009

Over 300 million patients use non-steroidal anti-inflammatory drugs (NSAIDs) in the world to treat pain, arthritis, fever and other diseases. Nearly 30% of the users suffer from gastric lesions and bleeding. To mitigate NSAIDs' adverse effects on the stomach, misoprostol, a non-selective prostaglandin E1 (PGE1) analogue, has been prescribed as the first choice for prevention of NSAID-induced injuries, but often induces severe adverse effects. There remain unmet medical needs for drugs with improved therapeutic profiles.

A research article published on November 7, 2009 in the World Journal of Gastroenterology addresses this question. A research team from United States investigated therapeutic potentials of a highly-selective EP4 agonist for treatment of a mouse gastric ulcer model in the presence or absence of indomethacin at various levels.

They found the EP4-selective agonist reduced high dose indomethacin-induced acute hemorrhagic damage and promoted mucous epithelial regeneration. Low-dose indomethacin aggravated ulcer bleeding and inflammation, and delayed the healing of the established chronic gastric ulcer. The EP4 agonist, when applied locally, not only offset indomethacin-induced gastric bleeding and inflammation, but also accelerated ulcer healing. In the absence of indomethacin, the EP4 agonist even accelerated chronic gastric ulcer healing and suppressed inflammatory cell infiltration in the granulation tissue. In vitro, the EP4 agonist protected human gastric mucous cells from indomethacin-induced apoptosis.

Their results suggest that EP4 agonists may mimic the gastric protective effects of PGE2 in the presence or absence of NSAIDs, and may show advantages over non-selective analogs such as misoprostol by minimizing adverse effects arising from activating all 4 subtype receptors of PGE2.


'/>"/>

Contact: Ye-Ru Wang
wjg@wjgnet.com
86-105-908-0039
World Journal of Gastroenterology
Source:Eurekalert

Page: 1

Related medicine news :

1. How IAP antagonist chemicals kill tumors
2. Exelixis to Receive Milestone Payment From Bristol-Myers Squibb for Achievement of Liver X Receptor Agonist Development Milestone
3. TNF-alpha antagonist stops inflammation-induced colon cancer in its tracks
4. TorreyPines Therapeutics Licenses Intellectual Property from Johns Hopkins Related to Novel Uses of Glutamate Receptor Antagonists for Prevention, Treatment of Stroke, Heart Attack
5. Galenea and Organix Announce Exclusive License Agreement for 5-HT2C Agonists for the Treatment of Obesity
6. TorreyPines NGX426, an Oral AMPA/Kainate Receptor Antagonist, Meets Primary Endpoints in Reducing Capsaicin-Induced Pain in Healthy Subjects
7. GlaxoSmithKline Statement on FDA Advisory Committee Vote on Use of Asthma Medicines Containing Long-Acting Beta-Agonists
8. Amira Announces the Successful Completion of GLP Toxicity Studies for a Novel DP2 Antagonist.
9. Shionogi Announces Positive Top-Line Efficacy Results from Year-Long Studies of Velneperit, a Novel NPY Y5 Receptor Antagonist Being Investigated for the Treatment of Obesity
10. Arena Pharmaceuticals Announces Initiation by Merck of Phase 2 Clinical Trial of Niacin Receptor Agonist
11. FDA Approves SAMSCA(TM) (tolvaptan), the First and Only Oral Vasopressin Antagonist to Treat Patients With Clinically Significant Hypervolemic and Euvolemic Hyponatremia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... ... today announced the release of two biometric time and attendance tracking products: the ... 4.0 software. NCheck Cloud Bio Attendance uses biometric face recognition to enable ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... The Executives, ... to raise money to for the Toys for Tots Literacy Campaign at their Semi-Annual ... in excess of $70 billion, the U.S. ranks at number 14 internationally in literacy. ...
(Date:3/28/2017)... ... March 28, 2017 , ... Prominant bariatric surgeon ... is thrilled to offer the recently FDA-approved Obalon Balloon System to his patients. ... SkyLex Advanced Surgical’s already comprehensive list of weight-loss services. Dr. Liu is ...
(Date:3/28/2017)... Francisco, CA (PRWEB) , ... March 28, 2017 , ... ... treatment, is proud to announce a new blog post about women’s hair loss. Although ... suffer from hair loss as they age. Menopause or genetics can be two reasons ...
(Date:3/28/2017)... ... , ... “A Prophets Bones”: a thrilling adventure that reveals the mystery of Kevin’s purpose. “A ... his parents and teachers had asked of him that he had neglected to do, but ... the Almighty Creator. There were some who would have felt themselves to be special and ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... , March 28, 2017  Medeon Biodesign, ... device company, is pleased to announce that the ... investment of Panther Orthopedics, Inc., a ... dynamic fixation solutions for orthopedic extremity applications.  ... to expand rapidly, primarily due to procedure volume ...
(Date:3/27/2017)... , March 27, 2017 ... clinical-stage pharmaceutical company specializing in the development of cannabinoid-based ... offering in the United States ... ADS representing 40 ordinary shares of the Company, ... addition, Therapix has granted the underwriters a 45-day ...
(Date:3/27/2017)... Medtec Europe will once ... 600 exhibitors from 70 countries the opportunity to ... will advance the medical technology industry. Taking place ... Stuttgart, Stuttgart, Germany , Medtec ... the key trends and insights across the entire ...
Breaking Medicine Technology: